Analysis of the published lung cancer datasets[19] showed that lung adenocarcinomas patients with higher levels of BIM expression had significantly shorter overall survival (OS) than did those expressing lower levels of BIM (Fig. 1). This evidence concerns the gene BCL2L11 and lung cancer.